niacin and HIV Coinfection
niacin has been researched along with HIV Coinfection in 27 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Pellagra is a clinical syndrome caused by a deficiency of niacin (nicotinic acid) and/or its precursor tryptophan." | 9.12 | Pellagra a review exploring causes and mechanisms, including isoniazid-induced pellagra. ( Dawe, RS; Mponda, K; Prabhu, D, 2021) |
"Pellagra is caused by niacin (vitamin B3) deficiency and patients with pellagra present with a characteristic rash." | 8.12 | Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study. ( Auld, AF; Buono, N; Chilikutali, L; Chisuwo, L; Chiwaula, MJ; da Silva, R; Girma, B; Gunde, LJ; Gutreuter, S; Jahn, A; Kalua, T; Kaunda, E; Kim, EJ; Kumwenda, T; Maida, A; Maphosa, T; Marshall, RE; Mbewe, K; Mekonnen, TF; Melgar, M; Mhango, V; Moffitt, A; Mponda, K; Mtoto, F; Muula, AS; Mwamale, S; Mwenyeheri, G; Nabity, SA; Nagoli, E; Ngongonda, D; Nyirenda, R; Odo, M; Oeltmann, JE; Sharma, AJ; Sunguti, J; Surie, D; Williams, AM; Woelk, G; Zimba, SB, 2022) |
"Niacin or tryptophan deficiency causes pellagra." | 8.02 | A peculiarly characterised case of isoniazid-induced pellagra- 2 Ds and a C: a case report. ( Kabengele, C; M'hango, H; Malumani, M; Mweemba, D, 2021) |
"Pellagra is a clinical syndrome caused by a deficiency of niacin (nicotinic acid) and/or its precursor tryptophan." | 5.12 | Pellagra a review exploring causes and mechanisms, including isoniazid-induced pellagra. ( Dawe, RS; Mponda, K; Prabhu, D, 2021) |
"Pellagra is caused by niacin (vitamin B3) deficiency and patients with pellagra present with a characteristic rash." | 4.12 | Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study. ( Auld, AF; Buono, N; Chilikutali, L; Chisuwo, L; Chiwaula, MJ; da Silva, R; Girma, B; Gunde, LJ; Gutreuter, S; Jahn, A; Kalua, T; Kaunda, E; Kim, EJ; Kumwenda, T; Maida, A; Maphosa, T; Marshall, RE; Mbewe, K; Mekonnen, TF; Melgar, M; Mhango, V; Moffitt, A; Mponda, K; Mtoto, F; Muula, AS; Mwamale, S; Mwenyeheri, G; Nabity, SA; Nagoli, E; Ngongonda, D; Nyirenda, R; Odo, M; Oeltmann, JE; Sharma, AJ; Sunguti, J; Surie, D; Williams, AM; Woelk, G; Zimba, SB, 2022) |
"Niacin or tryptophan deficiency causes pellagra." | 4.02 | A peculiarly characterised case of isoniazid-induced pellagra- 2 Ds and a C: a case report. ( Kabengele, C; M'hango, H; Malumani, M; Mweemba, D, 2021) |
"Pellagra is a systemic disorder caused by severe niacin deficiency." | 3.70 | [Prevalence of HIV infection in patients with pellagra and pellagra-like erythemas]. ( Kombate, K; Pitche, P; Tchangai-Walla, K, 1999) |
"Niacin was well-tolerated." | 2.72 | Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. ( Aberg, JA; Alston-Smith, BL; Deeg, MA; Dubé, MP; Greenwald, M; Lee, D; Martinez, AI; McGovern, ME; Shriver, SL; Stein, JH; Wu, JW, 2006) |
"ER-niacin's role in the treatment of antiretroviral therapy-associated dyslipidemia requires further evaluation, but the results of this pilot study indicate that it is safe and tolerated and provides a valuable treatment option." | 2.71 | Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. ( Claxton, S; DeMarco, D; Drechsler, H; Gerber, MT; Mondy, KE; Powderly, WG; Stoneman, J; Tebas, P; Yarasheski, KE, 2004) |
"Niacin has recently been demonstrated to lower blood pressure in hypertensive patients and to reduce cardiovascular events when combined with a statin." | 2.47 | Pellagra: a review with emphasis on photosensitivity. ( Anstey, A; Moat, S; Wan, P, 2011) |
"Lipodystrophy is defined as the defective metabolism of fat, and it is characterized by distinct physical changes, such as an increased waist size or an accumulation of fatty tissue at the base of the neck." | 1.30 | Update on lipodystrophy. ( Gaucher, M, 1999) |
Research
Studies (27)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (11.11) | 18.2507 |
2000's | 6 (22.22) | 29.6817 |
2010's | 14 (51.85) | 24.3611 |
2020's | 4 (14.81) | 2.80 |
Authors
Authors | Studies |
---|---|
Nabity, SA | 1 |
Mponda, K | 2 |
Gutreuter, S | 1 |
Surie, D | 1 |
Zimba, SB | 1 |
Chisuwo, L | 1 |
Moffitt, A | 1 |
Williams, AM | 1 |
Sharma, AJ | 1 |
Marshall, RE | 1 |
Chiwaula, MJ | 1 |
da Silva, R | 1 |
Kumwenda, T | 1 |
Chilikutali, L | 1 |
Mwamale, S | 1 |
Nagoli, E | 1 |
Mwenyeheri, G | 1 |
Ngongonda, D | 1 |
Kaunda, E | 1 |
Mtoto, F | 1 |
Mhango, V | 1 |
Mbewe, K | 1 |
Melgar, M | 1 |
Odo, M | 1 |
Jahn, A | 1 |
Buono, N | 1 |
Maida, A | 1 |
Girma, B | 1 |
Kalua, T | 1 |
Nyirenda, R | 1 |
Sunguti, J | 1 |
Woelk, G | 1 |
Gunde, LJ | 1 |
Mekonnen, TF | 1 |
Maphosa, T | 1 |
Kim, EJ | 1 |
Auld, AF | 1 |
Muula, AS | 1 |
Oeltmann, JE | 1 |
Lebouché, B | 2 |
Yero, A | 1 |
Shi, T | 1 |
Farnos, O | 1 |
Singer, J | 2 |
Kema, I | 1 |
Costiniuk, CT | 1 |
Thomas, R | 2 |
Brouillette, MJ | 2 |
Engler, K | 2 |
Routy, JP | 2 |
Jenabian, MA | 2 |
Kabengele, C | 1 |
M'hango, H | 1 |
Mweemba, D | 1 |
Malumani, M | 1 |
de Oliveira Alves, A | 1 |
Bortolato, T | 1 |
Bernardes Filho, F | 1 |
Gebhardt, A | 1 |
Fichtenbaum, CJ | 2 |
Gillard, BK | 2 |
Raya, JL | 1 |
Ruiz-Esponda, R | 1 |
Iyer, D | 1 |
Coraza, I | 2 |
Balasubramanyam, A | 2 |
Pownall, HJ | 2 |
Lin, C | 1 |
Grandinetti, A | 2 |
Shikuma, C | 2 |
Souza, S | 2 |
Parikh, N | 1 |
Nakamoto, B | 1 |
Kallianpur, KJ | 1 |
Chow, D | 1 |
Graziani, GM | 1 |
Trottier, B | 1 |
Sekhar, RV | 1 |
Dubé, MP | 2 |
Komarow, L | 1 |
Cadden, JJ | 1 |
Overton, ET | 1 |
Hodis, HN | 1 |
Currier, JS | 1 |
Stein, JH | 3 |
Tincati, C | 1 |
Savoldi, A | 1 |
Cannizzo, ES | 1 |
Bellistrì, GM | 1 |
Termini, R | 1 |
Garau, M | 1 |
Mancusi, D | 1 |
d'Arminio Monforte, A | 1 |
Marchetti, G | 1 |
Taylor, EW | 1 |
Chow, DC | 1 |
Seto, TB | 1 |
Mitchell, C | 1 |
Sriratanaviriyakul, N | 1 |
Gerschenson, M | 1 |
Shiramizu, B | 1 |
Oates, E | 1 |
Dzintars, K | 1 |
Wan, P | 1 |
Moat, S | 1 |
Anstey, A | 1 |
Grinspoon, S | 1 |
Fitch, K | 1 |
Wooten, JS | 1 |
Nambi, P | 1 |
Scott, LW | 1 |
Nambi, V | 1 |
Ballantyne, CM | 1 |
Fessel, WJ | 1 |
Follansbee, SE | 1 |
Rego, J | 1 |
Gerber, MT | 1 |
Mondy, KE | 1 |
Yarasheski, KE | 1 |
Drechsler, H | 1 |
Claxton, S | 1 |
Stoneman, J | 1 |
DeMarco, D | 1 |
Powderly, WG | 1 |
Tebas, P | 1 |
Currier, J | 1 |
Wu, JW | 1 |
Aberg, JA | 1 |
Deeg, MA | 1 |
Alston-Smith, BL | 1 |
McGovern, ME | 1 |
Lee, D | 1 |
Shriver, SL | 1 |
Martinez, AI | 1 |
Greenwald, M | 1 |
Tremeschin, MH | 1 |
Cervi, MC | 1 |
Camelo Júnior, JS | 1 |
Negrini, BV | 1 |
Martinez, FE | 1 |
Motta, F | 1 |
Meirelles, MS | 1 |
Vanucchhi, H | 1 |
Monteiro, JP | 1 |
Tang, AM | 1 |
Graham, NM | 1 |
Saah, AJ | 1 |
Gaucher, M | 1 |
Prabhu, D | 1 |
Dawe, RS | 1 |
Pitche, P | 1 |
Kombate, K | 1 |
Tchangai-Walla, K | 1 |
Clinical Trials (5)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy[NCT00246376] | 221 participants (Actual) | Interventional | 2004-01-31 | Completed | |||
Role of Extended-release Niacin on Immune Activation in HIV-infected Patients Treated With Antiretroviral Therapy: a Proof-of-concept Study[NCT02018965] | Phase 2 | 16 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
Effect of HDL-Raising Therapies on Endothelial Function, Lipoproteins, and Inflammation in HIV-infected Subjects With Low HDL Cholesterol: A Phase II Randomized Trial of Extended Release Niacin vs. Fenofibrate[NCT01426438] | Phase 2 | 99 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART[NCT01683656] | Phase 4 | 4 participants (Actual) | Interventional | 2012-08-31 | Terminated (stopped due to Withdrawal of IMP from the market. Data on risk-benefit ratio pending.) | ||
Prospective Randomized Pilot Study of the Effect of Niaspan on Endothelial Function in HIV-infected Subjects With Low HDL Cholesterol Levels[NCT00986986] | 20 participants (Actual) | Interventional | 2007-11-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
HDL-C
HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
Intervention | mg/dl (Mean) |
---|---|
Group 1 - Usual Care | 37.1 |
Group 2 - Diet/Exercise Only | 38.7 |
Group 3 - Diet/Exercise + Fenofibrate | 40.7 |
Group 4 - Diet/Exercise + Niacin | 41.8 |
Group 5 - Diet/Exercise + Fenofibrate + Niacin | 44.8 |
Non-HDL-C
non-HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
Intervention | mg/dl (Mean) |
---|---|
Group 1 - Usual Care | 162.2 |
Group 2 - Diet/Exercise Only | 165.4 |
Group 3 - Diet/Exercise + Fenofibrate | 145.8 |
Group 4 - Diet/Exercise + Niacin | 154 |
Group 5 - Diet/Exercise + Fenofibrate + Niacin | 137.1 |
Total Cholesterol
Total cholesterol (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
Intervention | mg/dL (Mean) |
---|---|
Group 1 - Usual Care | 195.6 |
Group 2 - Diet/Exercise Only | 200.1 |
Group 3 - Diet/Exercise + Fenofibrate | 184 |
Group 4 - Diet/Exercise + Niacin | 190.8 |
Group 5 - Diet/Exercise + Fenofibrate + Niacin | 178.4 |
Total Cholesterol : HDL-C Ratio
Total cholesterol : HDL-C ratio: Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
Intervention | ratio (Mean) |
---|---|
Group 1 - Usual Care | 5.2 |
Group 2 - Diet/Exercise Only | 5.1 |
Group 3 - Diet/Exercise + Fenofibrate | 4.5 |
Group 4 - Diet/Exercise + Niacin | 4.6 |
Group 5 - Diet/Exercise + Fenofibrate + Niacin | 4 |
Triglycerides
Triglycerides (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
Intervention | mg/dL (Mean) |
---|---|
Group 1 - Usual Care | 199 |
Group 2 - Diet/Exercise Only | 216.9 |
Group 3 - Diet/Exercise + Fenofibrate | 155.1 |
Group 4 - Diet/Exercise + Niacin | 177.6 |
Group 5 - Diet/Exercise + Fenofibrate + Niacin | 135.6 |
Body Composition
"Body cell mass (kg)~Fat mass (kg)" (NCT00246376)
Timeframe: Measured at 24 weeks
Intervention | kg (Mean) | |
---|---|---|
Body cell mass | Fat mass | |
Group 1 - Usual Care | 59.6 | 36.8 |
Group 2 - Diet/Exercise | 67.3 | 37.5 |
Group 3 - Diet/Exercise + Fenofibrate | 66.6 | 35.8 |
Group 4 - Diet/Exercise + Niacin | 67.1 | 37.7 |
Group 5 - Diet/Exercise + Fenofibrate + Niacin | 68.2 | 36.2 |
Insulin Sensitivity
Adiponectin (micrograms/ml) (NCT00246376)
Timeframe: Measured at 24 weeks
Intervention | micrograms/ml (Mean) | |||
---|---|---|---|---|
Fasting insulin | HOMA-IR | Insulin sensitvity index | Adiponectin | |
Group 1 - Usual Care | 8.7 | 1.92 | 3.54 | 7.12 |
Group 2 - Diet/Exercise Only | 6.7 | 1.38 | 4.95 | 6.04 |
Group 3 - Diet/Exercise + Fenofibrate | 9.5 | 2.02 | 3.81 | 5.24 |
Group 4 - Diet/Exercise + Niacin | 11.9 | 2.76 | 2.88 | 11.01 |
Group 5 - Diet/Exercise + Fenofibrate + Niacin | 10.3 | 2.38 | 2.38 | 10.34 |
Absolute Change in Relative FMD (%)
The absolute change in maximum relative flow mediated dilation (FMD) (%) of the brachial artery from baseline to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
Intervention | % FMD (Median) |
---|---|
Arm A: Extended-release Niacin With Aspirin | 0.60 |
Arm B: Fenofibrate | 0.50 |
Change in C-reactive Protein (CRP)
Change in C-reactive protein from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
Intervention | ug/ml (Median) |
---|---|
Arm A: Extended-release Niacin With Aspirin | -0.6 |
Arm B: Fenofibrate | 0.7 |
Change in Cholesterol
Absolute change in total cholesterol from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
Intervention | mg/dL (Median) |
---|---|
Arm A: Extended-release Niacin With Aspirin | -9 |
Arm B: Fenofibrate | -2 |
Change in D-Dimer
Change in D-Dimer from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks
Intervention | ug/ml (Median) |
---|---|
Arm A: Extended-release Niacin With Aspirin | 0.06 |
Arm B: Fenofibrate | 0.06 |
Change in HDL Particles
Change in total HDL particles from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks
Intervention | nmol/L (Median) |
---|---|
Arm A: Extended-release Niacin With Aspirin | -1.7 |
Arm B: Fenofibrate | 4.3 |
Change in HOMA-IR
Absolute change from week 0 to week 24 in insulin resistance as estimated by HOMA-IR (NCT01426438)
Timeframe: 0 and 24 weeks
Intervention | HOMA IR Score (Median) |
---|---|
Arm A: Extended-release Niacin With Aspirin | 1.3 |
Arm B: Fenofibrate | 0.3 |
Change in IL-6
Change in IL-6 from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks
Intervention | pg/ml (Median) |
---|---|
Arm A: Extended-release Niacin With Aspirin | 0.1 |
Arm B: Fenofibrate | 0.2 |
Change in Large HDL Particles
Change in Large HDL Particles from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks
Intervention | nmol/L (Median) |
---|---|
Arm A: Extended-release Niacin With Aspirin | 0.9 |
Arm B: Fenofibrate | -0.3 |
Change in LDL Cholesterol
Change in LDL cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
Intervention | mg/dL (Median) |
---|---|
Arm A: Extended-release Niacin With Aspirin | -1 |
Arm B: Fenofibrate | 7 |
Change in Non-HDL Cholesterol
Change in non-HDL Cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
Intervention | mg/dL (Median) |
---|---|
Arm A: Extended-release Niacin With Aspirin | -17 |
Arm B: Fenofibrate | -4 |
Change in Small LDL Particles
Change in Small LDL particles from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
Intervention | nmol/L (Median) |
---|---|
Arm A: Extended-release Niacin With Aspirin | -176 |
Arm B: Fenofibrate | -119 |
Change in Triglycerides
Change in Triglycerides (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
Intervention | mg/dL (Median) |
---|---|
Arm A: Extended-release Niacin With Aspirin | -65 |
Arm B: Fenofibrate | -54 |
Men: Change in HDL Cholesterol
Among men, change in HDL Cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
Intervention | mg/dL (Median) |
---|---|
Arm A: Extended-release Niacin With Aspirin | 3 |
Arm B: Fenofibrate | 6.5 |
Women: Change in HDL Cholesterol
Among women, change in HDL cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
Intervention | mg/dL (Median) |
---|---|
Arm A: Extended-release Niacin With Aspirin | 16 |
Arm B: Fenofibrate | 8 |
Change in Flow-mediated Vasodilation (FMD) From Baseline to Study Week 12
Brachial arterial flow-mediated dilation (FMD), assessed by high-resolution ultrasonography, reflects endothelium-dependent vasodilator function. The primary outcome is the change in FMD from baseline to study week 12. (NCT00986986)
Timeframe: Two time points (baseline and study week 12)
Intervention | percentage change in FMD (Median) |
---|---|
Extended Release Niacin | 6.36 |
Observation | 2.73 |
Flow Mediated Vasodilation
Flow mediated vasodilation is a marker of endothelial function (NCT00986986)
Timeframe: 12 weeks
Intervention | percentage change in FMD (Median) |
---|---|
Active Drug (Extended Release Niacin) | 4.51 |
Observation | 3.25 |
High-density Lipoprotein Cholesterol (HDL) Change From Baseline to Study Week 12
"HDL, often referred to Good cholesterol levels, will be obtained in both arms. HDL is a marker of coronary heart disease." (NCT00986986)
Timeframe: Two time points (baseline and study week 12)
Intervention | mg/dl (Median) |
---|---|
Active Drug (Extended Release Niacin) | 42.0 |
Observation | 27.0 |
Reviews
4 reviews available for niacin and HIV Coinfection
Article | Year |
---|---|
Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection.
Topics: Anti-Retroviral Agents; Drug Interactions; Dyslipidemias; Ezetimibe; HIV Infections; Humans; Hydroxy | 2019 |
Treatment of dyslipidemia in HIV.
Topics: Anti-HIV Agents; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diet Ther | 2015 |
Pellagra: a review with emphasis on photosensitivity.
Topics: Diet; Female; Genital Diseases, Female; Genital Diseases, Male; HIV Infections; Humans; Malabsorptio | 2011 |
Pellagra a review exploring causes and mechanisms, including isoniazid-induced pellagra.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Pel | 2021 |
Trials
10 trials available for niacin and HIV Coinfection
Article | Year |
---|---|
Impact of extended-release niacin on immune activation in HIV-infected immunological non-responders on effective antiretroviral therapy.
Topics: CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; HIV Infections; Humans | 2020 |
Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function.
Topics: Anti-Retroviral Agents; Biomarkers; Cell Line, Tumor; Cholesterol Esters; Combined Modality Therapy; | 2013 |
The effects of extended release niacin on lipoprotein sub-particle concentrations in HIV-infected patients.
Topics: Adult; Delayed-Action Preparations; Female; HIV Infections; Humans; Hypolipidemic Agents; Lipoprotei | 2013 |
The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy - CTN PT006: study protocol for a randomized controlled trial.
Topics: ADP-ribosyl Cyclase 1; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positi | 2014 |
Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.
Topics: Adult; Brachial Artery; C-Reactive Protein; Cholesterol, HDL; Delayed-Action Preparations; Dyslipide | 2015 |
Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Brachial Artery; CD4 Lymphocyte Count; Cholesterol, HDL; Dela | 2010 |
Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Brachial Artery; CD4 Lymphocyte Count; Cholesterol, HDL; Dela | 2010 |
Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Brachial Artery; CD4 Lymphocyte Count; Cholesterol, HDL; Dela | 2010 |
Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Brachial Artery; CD4 Lymphocyte Count; Cholesterol, HDL; Dela | 2010 |
Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Antiretroviral Therapy, Highly Active; | 2013 |
High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution.
Topics: Adipose Tissue; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cholesterol, HDL; Cyclopro | 2002 |
Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Cholesterol; Delayed-Action Preparations; Glucose Tolerance T | 2004 |
Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148.
Topics: Adult; Blood Glucose; Delayed-Action Preparations; Dyslipidemias; HIV Infections; Humans; Hypolipide | 2006 |
Other Studies
13 other studies available for niacin and HIV Coinfection
Article | Year |
---|---|
Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study.
Topics: Antitubercular Agents; Case-Control Studies; Exanthema; Female; HIV Infections; Humans; Isoniazid; M | 2022 |
A peculiarly characterised case of isoniazid-induced pellagra- 2 Ds and a C: a case report.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Constipation; Dementia; Dermatitis; Female; HIV Infec | 2021 |
Pellagra.
Topics: Alcoholism; Diarrhea; Exudates and Transudates; HIV Infections; Humans; Ill-Housed Persons; Male; Mi | 2018 |
T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study.
Topics: Adult; Anti-HIV Agents; Ascorbic Acid; Darunavir; Drug Combinations; Female; HIV Infections; HIV Pro | 2016 |
The oxidative stress-induced niacin sink (OSINS) model for HIV pathogenesis.
Topics: HIV Infections; HIV-1; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Models, Biological; Niacin; Oxi | 2010 |
Interaction between enfuvirtide, an injectable fusion inhibitor, and niacin in an HIV-infected patient.
Topics: Delayed-Action Preparations; Drug Interactions; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Pr | 2010 |
Therapy: HIV-associated dyslipidemia: the heart positive study.
Topics: Drug Therapy, Combination; Dyslipidemias; Exercise Therapy; Fenofibrate; Heart Diseases; HIV Infecti | 2011 |
Report from the 7th International Lipodystrophy Meeting.
Topics: Anti-HIV Agents; Dyslipidemias; HIV Infections; Humans; Lipodystrophy; Niacin | 2006 |
Side effects and complications. Extended-release high-dose niacin helps lower lipid levels.
Topics: Adult; Antiretroviral Therapy, Highly Active; Blood Glucose; CD4 Lymphocyte Count; Delayed-Action Pr | 2005 |
Niacin nutritional status in HIV type 1-positive children: preliminary data.
Topics: Cross-Sectional Studies; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; N | 2007 |
Effects of micronutrient intake on survival in human immunodeficiency virus type 1 infection.
Topics: Adult; Cohort Studies; Diet; HIV Infections; HIV-1; Humans; Male; Micronutrients; Niacin; Proportion | 1996 |
Update on lipodystrophy.
Topics: Diet; Disease Progression; Exercise; Female; HIV Infections; HIV Protease Inhibitors; Human Growth H | 1999 |
[Prevalence of HIV infection in patients with pellagra and pellagra-like erythemas].
Topics: Adolescent; Adult; Aged; Alcoholism; Cross-Sectional Studies; Erythema; Female; HIV Infections; HIV | 1999 |